Capital Expenditures - Denali Therapeutics Inc (NASDAQ:DNLI) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 20.77 USD -2.53%

Updated:

Denali Therapeutics Inc
Capital Expenditures

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Denali Therapeutics Inc
Capital Expenditures Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Capital Expenditures	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Denali Therapeutics Inc NASDAQ:DNLI	Capital Expenditures -$12.3m	CAGR 3-Years -35%	CAGR 5-Years -20%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Capital Expenditures -$795m	CAGR 3-Years 3%	CAGR 5-Years -5%	CAGR 10-Years -4%
	Gilead Sciences Inc NASDAQ:GILD	Capital Expenditures -$581m	CAGR 3-Years 3%	CAGR 5-Years 9%	CAGR 10-Years -6%
	Amgen Inc NASDAQ:AMGN	Capital Expenditures -$998m	CAGR 3-Years -16%	CAGR 5-Years -7%	CAGR 10-Years -4%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Capital Expenditures -$464.7m	CAGR 3-Years -14%	CAGR 5-Years -41%	CAGR 10-Years -25%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Capital Expenditures -$809.1m	CAGR 3-Years -13%	CAGR 5-Years -16%	CAGR 10-Years -15%

See Also

Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Capital Expenditures amounts to -12.3m USD.

Over the last year, the Capital Expenditures growth was 26%. The average annual Capital Expenditures growth rates for Denali Therapeutics Inc have been -35% over the past three years , -20% over the past five years .

Join more than 145,300+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.